Antibody-Based Treatment Approaches in Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33730360/
Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment...
-
Mark Fesler5yrThere are many more surface targets that have been identified in myeloma beyond cd38, slamf1, and bcma which is extremely exciting for the future of myeloma care
Autologous hematopoietic transplantation following COVID‐19 infection
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981617/
Marthilde Brzycki, 1 Robert Richard, 1 , 2 Nicholas Burwick, 1 , 2 Solomon Graf, 1 , 3 , 4 Craig O'Brien, 1 Daniel Wu, 1 , 3 and Thomas...
-
Mark Fesler5yrAn interesting report. More knowledge in this area is needed as clinicians presently face challenging decisions on balancing risks of malignancy and covid without a solid evidence base
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult...
-
Mark Fesler5yrAn expanded indication for a cd38 antibody, which are in key class of medications in the treatment of myeloma ...
Optic nerve head plasmacytoma as a manifestation of multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33767963/
Extramedullary disease in multiple myeloma is uncommon and associated with a poorer prognosis. Extramedullary disease involving the orbit is even more unusual, with optic nerve involvement being rare. We describe...
-
Mark Fesler5yrThe head and neck region seems to be a common site of extramedullary myeloma /plasmacytoma involvement for reasons that I’m not sure are well understood
FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has...
-
Mark Fesler5yrThis is a very exciting advance for the field of myeloma and ushers in a new era of treatment Existing treatment algorithms will require modification